Skip to main contentSkip to navigationSkip to search

Press release

Exercise of Camurus’ subscription warrant program 2019/2022

23 August 2022

Lund, Sweden23 August 2022 — During August 2022, a total of 301,200 subscription warrants in Camurus AB’s warrant program 2019/2022 have been exercised for the corresponding number of shares, at an exercise price of SEK 98.90 per share. Through the exercise of the subscription warrants Camurus receives SEK 29,788,680.

A number of employees and senior executives of Camurus, including the company’s CEO, have participated and have in a cashless exercise sold shares to finance the subscription of new shares and taxes related to the transaction. As a result of the transactions, the total shareholdings of the senior executives of Camurus have increased with 17,712 shares, corresponding to 1.0 percent of their total holdings.

The exercise period for warrant program 2019/2022 ends on 15 December 2022.

For more information
Fredrik Tiberg, President & CEO
Tel. +46 (0)46 286 46 92

fredrik.tiberg@camurus.com

Fredrik Joabsson, Chief Business Development Officer
Tel. +46 (0)70 776 17 37

ir@camurus.com

About Camurus
Camurus is a Swedish science-led biopharmaceutical company committed to developing and commercialising innovative and differentiated medicines for the treatment of severe and chronic conditions. New drug products with best-in-class potential are conceived based on the company’s proprietary FluidCrystal® drug delivery technologies and its extensive R&D expertise. Camurus’ clinical pipeline includes products for the treatment of cancer, endocrine diseases, pain and addiction, which are developed in-house and in collaboration with international pharmaceutical companies. The company’s shares are listed on Nasdaq Stockholm under the ticker CAMX. For more information, visit www.camurus.com.

The information was submitted for publication at 07:00 am CET on 23 August 2022.